24 Hrs
Source:
المشهد العربي
Source: المشهد العربي
24 Hrsالمشهد العربي
Source: المشهد العربي
24 HrsReady to play
Ready to play
The U.S. Food and Drug Administration rejected ivonescimab, Summit Therapeutics’ lung cancer drug, after reviewing its marketing application. A late-stage trial showed that the drug significantly slowed disease progression, but it did not produce a statistically significant improvement in survival—a key measure of its long-term benefit.
Notice: This Is an AI-Generated Summary
Comments (0)